Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

CC 99712

Next Previous
Drug Profile

CC 99712

Alternative Names: Anti-BCMA antibody drug conjugate - Celgene/Sutro; Antibody drug conjugates - Celgene/Sutro; CC 99712

Latest Information Update: 13 Sep 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Sutro Biopharma
  • Developer Celgene Corporation; Sutro Biopharma
  • Class Antibodies; Antineoplastics; Drug conjugates; Immunoconjugates
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Multiple myeloma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Multiple myeloma

Most Recent Events

  • 30 Aug 2024 Celgene terminates phase-I clinical trials in Multiple myeloma (Combination therapy, Second-line therapy or greater) in US, Canada, France, Italy and Spain due to slow accrual (IV) (NCT04036461)
  • 07 Oct 2023 Bristol Myers Squibb (BMS) terminates the BMS Agreement and stopping development of CC 99712 due to a portfolio prioritization decision
  • 26 Jun 2023 CC 99712 is still in phase I trials for Multiple myeloma (Combination therapy, Second line therapy or greater) in France, USA, Canada, Italy, Spain (IV, Infusion) (NCT04036461)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top